Ryan Christopher Wong

Assistant Clinical Professor, Medicine - (Clinical Series Track)

Contact

(520) 626-6453
AHSC, Rm. 2301
TUCSON, AZ 85724-5099
rcwong88@arizona.edu

Degrees

M.D. Medicine

University of Arizona, Tucson, Arizona, United States

B.S. Biology - Biomedical Sciences w/ Honors, summa cum laude

University of Arizona, Tucson, Arizona, United States

Awards

Internal Medicine Graduation Keynote Speaker

University of Arizona Internal Medicine Residency Program, Spring 2022

Outstanding Consultant

University of Washington Medical Center, Fall 2019

Licensure & Certification

Board Certified, Nephrology, ABIM (2021)
Board Certified, Internal Medicine, ABIM (2018)

Interests

Research

Home Dialysis ModalitiesContinuous Renal Replacement TherapyFabry Disease Neph-Onc

Teaching

Medical Education

Courses

2025-26 Courses

Honors Thesis

BSM 498H (Fall 2025)

Scholarly Contributions

Journals/Publications

Al-Obaidi, M. M., Gungor, A. B., Murugapandian, S., Thajudeen, B., Mansour, I., Wong, R. C., Tanriover, B., & Zangeneh, T. T. (2023). The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era. The American journal of medicine.
More info
The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality in high-risk populations. Several therapeutics have been developed to reduce the risk of complications related to COVID-19, hospitalizations, and death. In several studies, nirmatrelvir-ritonavir (NR) was reported to reduce the risk of hospitalizations and death. We aimed to evaluate the efficacy of NR in preventing hospitalizations and death during the Omicron predominant period.

Edit my profile